CLIMB BIO INC (CLYM) Stock Income Statement
USA - NASDAQ:CLYM - US28658R1068 - Common Stock
1.9 USD
+0.03 (+1.6%)
1.9 USD
0 (0%)
| TTM (2025-9-30) | 2024 (2024-12-31) | 2023 (2023-12-31) | 2022 (2022-12-31) | 2021 (2021-12-31) | ||||
|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | |||
| Gross Premiums Earned | null | null | null | null | null | |||
| Loss Claims | null | null | null | null | null | |||
| Deferred Policy Acquisition Expense | null | null | null | null | null | |||
| Net Interest Income | null | null | null | null | null | |||
| Non Interest Income | null | null | null | null | null | |||
| Loan Loss Provision | null | null | null | null | null | |||
| Net Interest Income after Provision | null | null | null | null | null | |||
| Non Interest Expense | null | null | null | null | null | |||
| Minority Interest Expense | null | null | null | null | null | |||
| Cost Of Goods | null | null | null | null | null | |||
| Gross Profit | null | null | null | null | null | |||
| Operating Expenses | 56.14M | 27.00M | 21.47M | 45.14M | 35.67M | |||
| Research and Development | 36.21M | 11.61M | 11.58M | 26.21M | 23.32M | |||
| Selling, General, and Administrative Expenses | 19.93M | 15.39M | 9.89M | 18.92M | 12.35M | |||
| Operating Income | -56.14M | -27.00M | -21.47M | -45.14M | -35.67M | |||
| Interest Income/Expense | 8.75M | 8.12M | 5.16M | -1.48M | -170.00K | |||
| Other Income/Expense | null | null | null | 1.38M | -11.64M | |||
| Non Recurring Items | null | -55.02M | -18.81M | null | null | |||
| Income Before Taxes | -50.75M | -73.90M | -35.12M | -45.24M | -47.48M | |||
| Income Tax | null | null | null | null | null | |||
| Net Income | -50.75M | -73.90M | -35.12M | -45.24M | -52.03M | |||
| EBITDA | null | undefined | undefined | undefined | undefined | |||
| Per Share Data | ||||||||
| EPS Diluted Total Ops | -0.7505999999999999 | -1.5343 | -1.3013 | -1.72 | -4.24 | |||
| Non GAAP EPS | -0.76 | null | null | -1.72 | null | |||
| Statistics | ||||||||
All data in USD